NASDAQ:CARA - Cara Therapeutics Stock Price, Forecast & News

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics Inc (NASDAQ:CARA) released its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.05. The biopharmaceutical company had revenue of $4.51 million for the quarter, compared to analyst estimates of $5.58 million. Cara Therapeutics had a negative net margin of 470.70% and a negative return on equity of 70.35%. View Cara Therapeutics' Earnings History.

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Cara Therapeutics.

4 brokerages have issued 12-month target prices for Cara Therapeutics' shares. Their forecasts range from $30.00 to $39.00. On average, they expect Cara Therapeutics' stock price to reach $33.80 in the next twelve months. This suggests a possible upside of 124.9% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.

News articles about CARA stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cara Therapeutics earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Cara Therapeutics.

Cara Therapeutics saw a decrease in short interest in January. As of January 31st, there was short interest totalling 4,850,000 shares, a decrease of 9.7% from the January 15th total of 5,370,000 shares. Based on an average trading volume of 729,500 shares, the short-interest ratio is presently 6.6 days. Approximately 11.4% of the shares of the company are short sold. View Cara Therapeutics' Current Options Chain.

Some companies that are related to Cara Therapeutics include Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), SAGE Therapeutics (SAGE), ArQule (ARQL), Uniqure (QURE), Principia Biopharma (PRNB), Synthorx (THOR), Ra Pharmaceuticals (RARX), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), Insmed (INSM), Forty Seven (FTSV), Cambrex (CBM), Aurinia Pharmaceuticals (AUPH) and Prestige Consumer Healthcare (PBH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Canopy Growth (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), 22nd Century Group (XXII), Insys Therapeutics (INSY), Fate Therapeutics (FATE), GW Pharmaceuticals PLC- (GWPH), Novavax (NVAX) and BioMarin Pharmaceutical (BMRN).

Cara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Wealth Quarterback LLC (351.62%), Farallon Capital Management LLC (5.75%), Chescapmanager LLC (3.25%), State Street Corp (2.50%), Franklin Resources Inc. (1.41%) and Geode Capital Management LLC (1.35%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Institutional Ownership Trends for Cara Therapeutics.

CARA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Ladenburg Thalmann Financial Services Inc., Franklin Resources Inc., Exane Derivatives, DekaBank Deutsche Girozentrale and Advisor Group Inc.. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Mani Mohindru and Scott Terrillion. View Insider Buying and Selling for Cara Therapeutics.

CARA stock was bought by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, Bank of America Corp DE, Cypress Capital Management LLC WY, Farallon Capital Management LLC, Pinnacle Associates Ltd., J. Goldman & Co LP, AdvisorShares Investments LLC and State Street Corp. View Insider Buying and Selling for Cara Therapeutics.

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CARA stock can currently be purchased for approximately $15.03.

Cara Therapeutics has a market capitalization of $601.62 million and generates $13.47 million in revenue each year. The biopharmaceutical company earns $-74,010,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.View Additional Information About Cara Therapeutics.

The official website for Cara Therapeutics is http://www.caratherapeutics.com/.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.